Momelotinib cyt387

The human SNU-387 and SNU-475 HCC cell lines were purchased from American Tissue Culture Collection (ATCC). The cells were maintained under conditions recommended by the vendor, cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Thermo Fisher Scientific Inc., Waltham, MA, USA.) supplemented with 10% fetal bo-vine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, Life Technologies, Saint-Louis, MO, USA) at 37 °C, in a 5% humidified CO₂ incubator. THLE-2 cell line was derived from primary normal liver cells by infection with SV40 large T antigen, HepG₂ was derived from a liver hepatocellular carcinoma both were purchased from ATCC. THLE-2 and HepG₂ cell lines were maintained in DMEM medium (Dulbecco’s Modified Eagle Medium; Gibco, Invitrogen), and all cells were incubated at 37 °C in a humidified incubator containing 5% CO₂ in air. Cells were sub-cultured at 80–90% confluency. The Jak inhibitor momelotinib (CYT387) [21 (link)] and sorafenib (Catalog No. S7397), purchased from Selleck Chemicals, were dissolved in DMSO.